Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 8
1946 14
1947 35
1948 57
1949 50
1950 79
1951 113
1952 101
1953 111
1954 106
1955 81
1956 115
1957 105
1958 101
1959 74
1960 89
1961 72
1962 107
1963 274
1964 445
1965 300
1966 369
1967 535
1968 565
1969 671
1970 731
1971 789
1972 804
1973 873
1974 974
1975 878
1976 893
1977 929
1978 975
1979 1094
1980 1252
1981 1301
1982 1334
1983 1503
1984 1564
1985 1669
1986 1585
1987 1621
1988 1622
1989 1596
1990 1549
1991 1573
1992 1432
1993 1359
1994 1236
1995 1211
1996 1148
1997 1134
1998 1103
1999 1106
2000 1073
2001 1082
2002 1051
2003 1020
2004 1043
2005 1051
2006 1107
2007 1069
2008 1019
2009 967
2010 999
2011 971
2012 996
2013 981
2014 953
2015 875
2016 853
2017 802
2018 772
2019 731
2020 678
2021 574
2022 547
2023 462
2024 192

Text availability

Article attribute

Article type

Publication date

Search Results

60,887 results

Results by year

Filters applied: . Clear all
Page 1
Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction.
Goldstein I. Goldstein I. Int J Impot Res. 2000 Mar;12 Suppl 1:S75-80. Int J Impot Res. 2000. PMID: 10845768 Review.
Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist which has undergone clinical trials for erectile dysfunction treatment. Biochemical and physiological studies in human erectile tissue have revealed a high affinit …
Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist which has undergone cli …
Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
Frishman WH, Eisen G, Lapsker J. Frishman WH, et al. Med Clin North Am. 1988 Mar;72(2):441-8. doi: 10.1016/s0025-7125(16)30778-7. Med Clin North Am. 1988. PMID: 2894488 Review.
Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist. Its pharmacokinetic and pharmacodynamic profiles are similar to those of prazosin, but terazosin has a half-life three to four times longer. ...
Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist. Its pharmacokinetic and pharmacodynamic profil …
Management of benign prostate hyperplasia: an overview of alpha-adrenergic antagonist.
Garg G, Singh D, Saraf S, Saraf S. Garg G, et al. Biol Pharm Bull. 2006 Aug;29(8):1554-8. doi: 10.1248/bpb.29.1554. Biol Pharm Bull. 2006. PMID: 16880603 Free article. Review.
In hyperplastic prostate tissue, the prostate capsule, and the bladder neck are blocked, by using alpha-adrenergic antagonist drugs; the smooth muscle tone of these structures is decreased. As a result, resistance to urinary flow through the bladder neck and …
In hyperplastic prostate tissue, the prostate capsule, and the bladder neck are blocked, by using alpha-adrenergic antagoni …
Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR. Guay DR. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23. doi: 10.1016/s1543-5946(04)90003-7. Am J Geriatr Pharmacother. 2004. PMID: 15555475 Review.
BACKGROUND: Extended-release (ER) alfuzosin hydrochloride is the most recently approved alpha-adrenergic receptor antagonist (AARA) for the management of symptomatic benign prostatic hyperplasia (BPH). ...METHODS: Relevant articles were identified through MED …
BACKGROUND: Extended-release (ER) alfuzosin hydrochloride is the most recently approved alpha-adrenergic receptor antagonis …
Doxazosin: a new alpha 1-adrenergic antagonist.
Babamoto KS, Hirokawa WT. Babamoto KS, et al. Clin Pharm. 1992 May;11(5):415-27. Clin Pharm. 1992. PMID: 1349855 Review.
The physicochemical properties, pharmacology, pharmacokinetics, cardiovascular and metabolic effects, adverse effects, dosage, and administration of doxazosin are described, and comparative clinical studies of doxazosin therapy in patients with mild to moderate hypertension are r …
The physicochemical properties, pharmacology, pharmacokinetics, cardiovascular and metabolic effects, adverse effects, dosage, and administr …
Atipamezole.
El Bahri L. El Bahri L. Compend Contin Educ Vet. 2008 May;30(5):256-8. Compend Contin Educ Vet. 2008. PMID: 18581288 Review.
Learn about the pharmacology, applications, and administration of this alpha2-adrenergic antagonist....
Learn about the pharmacology, applications, and administration of this alpha2-adrenergic antagonist....
Chemokine receptor antagonists with alpha(1)-adrenergic receptor blocker activity.
DeSantis AJ, Enten GA, Gao X, Majetschak M. DeSantis AJ, et al. J Basic Clin Physiol Pharmacol. 2021 Jun 21;33(4):519-523. doi: 10.1515/jbcpp-2020-0523. J Basic Clin Physiol Pharmacol. 2021. PMID: 34144642 Free PMC article.
OBJECTIVES: Chemokine receptor antagonists are being explored for their therapeutic potential in various disease processes. As the chemokine (C-C motif) receptor 2 (CCR2) antagonist RS504393 is known to compete with ligand binding to alpha(1)-adrenoceptors, we teste …
OBJECTIVES: Chemokine receptor antagonists are being explored for their therapeutic potential in various disease processes. As the chemokine …
Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement.
Wada N, Abe N, Miyauchi K, Ishikawa M, Makino S, Kakizaki H. Wada N, et al. Int Urol Nephrol. 2022 Jan;54(1):31-36. doi: 10.1007/s11255-021-03053-9. Epub 2021 Nov 12. Int Urol Nephrol. 2022. PMID: 34767140
PURPOSE: To identify the clinical factors resulting in the failure of dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement (BPE). METHODS: We retrospectively surveyed the p …
PURPOSE: To identify the clinical factors resulting in the failure of dutasteride add-on treatment to alpha-adrenergic anta …
Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure.
Dhaliwal AS, Habib G, Deswal A, Verduzco M, Souchek J, Ramasubbu K, Aguilar D, Ma TS, Jneid HM, Bolos M, Bozkurt B. Dhaliwal AS, et al. Am J Cardiol. 2009 Jul 15;104(2):270-5. doi: 10.1016/j.amjcard.2009.03.030. Am J Cardiol. 2009. PMID: 19576359
We sought to determine any association between alpha(1)-adrenergic antagonist use, commonly prescribed for benign prostatic hyperplasia, and the clinical outcomes of subjects with HF receiving contemporary therapy. ...Thus, background beta-blocker therapy app …
We sought to determine any association between alpha(1)-adrenergic antagonist use, commonly prescribed for benign prost …
Napamezole, an alpha-2 adrenergic receptor antagonist and monoamine uptake inhibitor in vitro.
Perrone MH, Hamel LT, Ferrari RA, Haubrich DR. Perrone MH, et al. J Pharmacol Exp Ther. 1990 Aug;254(2):471-5. J Pharmacol Exp Ther. 1990. PMID: 1974637
Napamezole (2-[3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydro-1H- imidazole-monohydrochloride) is a selective alpha-2 adrenergic receptor antagonist and a monoamine re-uptake inhibitor in vitro. The alpha adrenergic antagonist activity of …
Napamezole (2-[3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydro-1H- imidazole-monohydrochloride) is a selective alpha-2 adrenergic …
60,887 results
You have reached the last available page of results. Please see the User Guide for more information.